In this respect, a number of myostatin inhibitors are currently being tested in Phase II/III clinical trials for a variety of indications characterized by muscle loss, including cancer, hip replacement surgery, age-related sarcopenia, end-stage renal disease, chronic obstructive pulmonary disease and inclusion body myositis (see clinicaltrials.gov). The gene discussed is MSTN; the disease is stage 5 chronic kidney disease.